GSM Foils Q4 FY26: Rapid Scale-Up Meets Working Capital Stress

GSM Foils Limited, a manufacturer of blister foils and aluminium strip pharma foils, closed Q4 FY26 with a sharp jump in scale. Revenue for Q4 FY26 came in at 81.7 crore, up 79.1% year-on-year. EBITDA rose 62.5% year-on-year to 9.4 crore, while profit after tax increased 83.6% to 6.3 crore.

For FY26, the company reported revenue of 258.2 crore, a 92.9% year-on-year increase. EBITDA nearly doubled to 29.8 crore, and PAT climbed to 19.8 crore, with PAT margin improving to 7.7% from 7.2% in FY25.

The headline numbers show strong operating leverage from higher volumes. But both the financial statements and management commentary also highlight the other side of the story. Working capital expanded materially, and cash generation remained negative as receivables and inventories rose alongside growth.

Q4 and FY26 performance: growth strong, margins mixed

In Q4 FY26, gross profit margin declined to 15.0% from 18.3% in Q4 FY25. Management attributed pressure to sharp increases in aluminium prices and higher costs of petrochemical derivatives and intermediates used in pharma packaging. The company indicated that price increases were largely passed through, but with a lag and some near-term absorption.

EBITDA margin in Q4 FY26 moderated to 11.5% from 12.7% a year earlier. However, PAT margin improved slightly to 7.7% from 7.5%, indicating that while operating costs faced pressure, net profitability remained stable.

For the full year, EBITDA margin stayed broadly steady at 11.5% compared to 11.4% in FY25. PAT margin improved to 7.7% versus 7.2%. The ratio slide in the presentation also reported ROCE of 39.9% in FY26 and ROE of 26.6%.

Capacity expansion: Ahmedabad ramps up, Vasai still has headroom

A key theme in both the presentation and the earnings call was the company’s capacity expansion through a new manufacturing facility in Ahmedabad, Gujarat.

The investor presentation describes the Ahmedabad unit as a strategic capacity expansion with around 17,000 sq ft leased area and 10,000+ MT annual capacity. The company targets optimum utilisation by March 2027. Total capital expenditure is indicated at about 5 to 6 crore.

On the call, management stated the Ahmedabad facility had reached around 25% to 30% utilisation. They also shared a revenue potential metric. At optimal utilisation, the Ahmedabad plant could deliver a monthly run-rate of around 30 to 35 crore. For context, management stated that in March 2026, Ahmedabad contributed around 5 to 5.5 crore revenue.

The legacy Vasai facility, according to management, is operating at around 25 to 28 crore per month and still has around 10% capacity left. Management added that with spares and certain additions, Vasai’s capacity could be increased by up to 20%, implying an additional 6 to 7 crore per month revenue potential.

Taken together, management described a vision of reaching around 60 crore per month in combined revenue run-rate as Ahmedabad ramps up and Vasai capacity is further unlocked.

The real constraint: working capital, receivables, and funding

The call made it clear that management views working capital as the primary competitive edge in this business. They described the sector as a basic pharma packaging business with low entry barriers, where success depends on the ability to manage credit cycles, procure inputs, and keep operations running without cash crunch.

This focus is visible in the balance sheet. Trade receivables increased sharply to 94.315 crore at March 2026 from 33.766 crore at March 2025. Inventories also rose to 47.044 crore at March 2026 from 18.860 crore a year earlier. Short-term borrowings increased to 44.391 crore at March 2026 from 17.820 crore at March 2025.

Management attributed the March spike in receivables to delayed customer payments during the period of heightened geopolitical disruptions, with certain export-linked payments and LCs getting delayed. They stated that a substantial portion of receivables, around 30 to 40 crore, had already been received in early April.

Cash flows underline the strain. FY26 operating cash flow was negative at -36.793 crore, driven by a working capital outflow of -66.576 crore. The company funded this through financing cash flows of 46.963 crore in FY26.

From an execution perspective, the near-term question is whether growth can continue while bringing receivables and the cash conversion cycle closer to normal levels.

What management said about FY27 and next steps

Management offered a topline estimate for the next year. They stated that even with a normal year, FY27 topline could be around 400 to 450 crore.

On margins, management indicated it would try to sustain current EBITDA margin levels around 11.5%, while noting that input costs remain volatile and the time to normalisation is uncertain.

On longer-term capex, management indicated that once the Ahmedabad facility stabilises, it may look at forward integration. This includes setting up specialised printing and conversion units to cater to pharma customers, including exports. They stated they are not currently looking at backward integration.

Takeaways

GSM Foils delivered a strong FY26 on revenue and profit growth, backed by increased scale and ramp-up of newer capacity. The Ahmedabad plant is positioned as the next growth driver, with a clear utilisation target by March 2027 and quantified capex disclosure.

At the same time, the company’s financials show that growth has come with a sharp expansion in working capital, especially receivables. Management acknowledges this as a structural feature of the pharma packaging business and frames working capital discipline as the primary moat.

For investors tracking FY27 execution, the key monitorables remain the Ahmedabad ramp-up pace, the stability of input costs and pricing pass-through, and the company’s ability to normalise receivables while scaling toward the topline range management discussed.